Autonomix Medical CEO to Present at LSI USA ’26, Highlighting Nerve-Targeted Pain Treatment
Event summary
- Autonomix Medical CEO Brad Hauser to present at LSI USA ’26 on March 17, 2026, at 9:15 AM PT.
- Company to host in-person one-on-one meetings with investors at the conference.
- Autonomix focuses on nerve-targeted treatments, initially for pancreatic cancer pain.
- Technology platform includes a catheter-based microchip sensing array for neural signal detection.
- Product is investigational and not yet cleared for marketing in the U.S.
The big picture
Autonomix Medical’s participation in LSI USA ’26 underscores the growing interest in precision nerve-targeted treatments, particularly for conditions like pancreatic cancer pain where current solutions are inadequate. The company’s platform technology positions it at the forefront of a broader shift toward transvascular diagnostics and therapies in the medtech sector. Success will hinge on clinical validation and regulatory approval, as well as the ability to scale across multiple indications.
What we're watching
- Clinical Validation
- How Autonomix’s nerve-targeted technology performs in initial trials for pancreatic cancer pain.
- Market Expansion
- Whether the company can successfully pivot its platform to other indications like cardiology and hypertension.
- Regulatory Progress
- The pace at which Autonomix secures marketing clearance for its investigational device in the U.S.